Immunogenicity and autoimmunity during anti-TNF therapy

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 703-708

  Atzeni, F ^a   Talotta, R ^a   Salaffi, F ^b   Cassinotti, A ^a   Varisco, V ^a   Battellino, M ^a   Ardizzone, S ^a   Pace, F ^a   Sarzi Puttini, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anti nuclear antibodies; Autoantibodies against drugs; Autoimmunity; TNF agents

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; DRUG ANTIBODY; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; METHOTREXATE; NEUTRALIZING ANTIBODY; NUCLEOSOME ANTIBODY; PHOSPHOLIPID ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE INFUSION REACTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877809247     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.021     Document Type: Review

References (43)

1. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
2. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012, 380(9853):1590-1605.
3. Atzeni F., Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 2009, 10:1204-1211.
4. Caprioli F., Pallone F., Monteleone G. Cytokine therapies in Crohn's disease: where are we now and where should we go?. Inflamm Allergy Drug Targets 2011, 10:47-53.
5. Atzeni F., Benucci M., Sallì S., Bongiovanni S., Boccassini L., Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 2013, 12(5):575-579.
6. Atzeni F., Sarzi-Puttini P. Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev Clin Immunol 2008, 4:275-280.
7. Cassinotti A., Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009, 15:1264-1275.
8. Vultaggio A., Matucci A., Nencini F., Pratesi S., Parronchi P., Rossi O., et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657-661.
9. Bendtzen K., Ainsworth M., Steenholdt C., Thomsen O.O., Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 44:774-781.
10. Chaparro M., Guerra I., Muñoz-Linares P., Gisbert J.P. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012, (Mar 22). http://dx.doi.org/10.1111/j.1365-2036.2012.05057.x [Epub ahead of print].
11. Aikawa N.E., Freire de Carvalho J., Almeida Silva C.A., Bonfà E. Immunogenicity of Anti-TNF-α agents in autoimmune diseases. Clin Rev Allergy Immunol 2010, 38:82-89.
12. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
13. Farrell R.J., Alsahli M., Jeen Y.T., Falchuk K.R., Peppercorn M.A., Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
14. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 2359:1541-1549.
15. Ainsworth M.A., Bendtzen K., Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008, 103:944-948.
16. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
17. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
18. Steenholdt C., Svenson M., Bendtzen K., Thomsen O.O., Brynskov J., Ainsworth M. Can measurements of anti-infliximab antibodies predict acute severe infusion reactions to infliximab?. Gastroenterology 2011, 140:S774.
19. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
20. Pascual-Salcedo D., Plasencia C., Ramiro S., Nuño L., Bonilla G., et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:1445-1452.
21. van der Bijl A.E., Breedveld F.C., Antoni C.E., Kalden J.R., Kary S., Burmester G.R., et al. An open label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008, 27:1021-1028.
22. van der Maas A., van den Bemt B.J., Wolbink G.J., van den Hoogen F.H., van Riel P.L., den Broeder A.A. Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskelet Disord 2012, 13:184.
23. Klareskog L., Gaubitz M., Rodríguez-Valverde V., Malaise M., Dougados M., Wajdula J. Etanercept Study 301 Investigators. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:238-247.
24. Sandborn W.J., Hanauer S.B., Rutgeerts P.J., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
25. Bender N.K., Heilig C.E., Dröll B., Wohlgemuth J., Armbruster F.P., Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007, 27:269-274.
26. West R.L., Zelinkova Z., Wolbink G.J., Kuipers E.J., Stokkers P.C., van der Woude C.J. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008, 28:1122-1126.
27. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
28. Benucci M., Li Gobbi F., Baiardi P., Sarzi-Puttini P., Manfredi M., Atzeni F. Lack of correlation between the development of IgA and IgM specific antibodies to anti-TNF blocking agents, disease activity and adverse side reactions in a longitudinal study of rheumatoid arthritis. Ann Rheum Dis 2011, 70(Suppl. 3):120.
29. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with Infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomised placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
30. De Rycke L., Kruithof E., Van Damme N., Hoffman I.E., Van den Bossche N., Van den Bosch F., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-1023.
31. De Rycke L., Baeten D., Kruithof E., Van de Bosch F., Veys E.M., De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005, 52:2192-2201. [Arthritis Rheum. 2005; 52, 2192-201].
32. Ferraccioli G., Mecchia F., Di Poi E., Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002, 61:358-361.
33. Jonsdottir T., Forslid J., van Vollenhoven A., Harju A., Brannemark S., Klareskog L., et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004, 63:1075-1078.
34. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., de Portu S., Cecchini G., Cruini C., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one year prospective study. Arthritis Res Ther 2006, 8(1):R3.
35. Atzeni F., Ardizzone S., Sarzi-Puttini P., Colombo E., Maconi G., De Portu S., et al. Autoimmunity profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther 2005, 22:453-461.
36. Fusconi M., Vannini A., Dall'aglio A.C., Pappas G., Bianchi F.B., Zauli D. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis. Rheumatol Int 2007, 28(1):47-49. [Epub 2007 Jun 13].
37. Benucci M., Saviola G., Baiardi P., Cammelli E., Manfredi M. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFα blocking agents in rheumatoid arthritis. Clin Rheumatol 2008, 27:91-95.
38. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007, 86:242-251.
39. Catrina A.I., Trollmo C., af Klint E., Engstrom M., Lampa J., Hermansson Y., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72.
40. Bickerstaff M.C., Botto M., Hutchinson W.L., Herbert J., Tennent G.A., Bybee A., et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear auto-immunity. Nat Med 1999, 5:694-697.
41. Bauer M., Heeg K., Wagner H., Lipford G.B. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 1999, 97:699-705.
42. Ramos-Casals M., Roberto-Perez-Alvarez, Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193. BIOGEAS Study Group.
43. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011, 10:563-568.